Suchen
Mediwound Ltd
MDWDZur Watchlist hinzufügen
15.160USD
+0.340+2.29%
Handelsschluss 07/02, 13:00（ET）Kurse um 15 Minuten verzögert
194.84MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Mediwound Ltd Unternehmen
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
Mediwound Ltd Informationen
BörsenkürzelMDWD
Name des UnternehmensMediwound Ltd
IPO-datumMar 20, 2014
CEOGonen (Ofer)
Anzahl der mitarbeiter111
WertpapierartOrdinary Share
GeschäftsjahresendeMar 20
Addresse42 Hayarkon Street
StadtYAVNE
BörseNASDAQ OMX - NASDAQ BASIC
LandIsrael
Postleitzahl8122745
Telefon972779714100
Websitehttps://www.mediwound.com/
BörsenkürzelMDWD
IPO-datumMar 20, 2014
CEOGonen (Ofer)
Führungskräfte von Mediwound Ltd
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Ofer Gonen
Mr. Ofer Gonen
Chief Executive Officer, Director
Chief Executive Officer, Director
275.42K
+33.88%
Dr. Vickie R. Driver, M.D.
Dr. Vickie R. Driver, M.D.
Independent Director
Independent Director
--
--
Mr. Stephen T. Wills, CPA
Mr. Stephen T. Wills, CPA
Independent Director
Independent Director
--
--
Dr. Ety Klinger, Ph.D.
Dr. Ety Klinger, Ph.D.
Chief Research and Development Officer
Chief Research and Development Officer
--
--
Mr. Yaron Meyer
Mr. Yaron Meyer
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
--
--
Mr. David Fox
Mr. David Fox
Independent Director
Independent Director
--
--
Mr. Jeremy Feffer
Mr. Jeremy Feffer
Managing Director
Managing Director
--
--
Mr. Shmuel (Milky) Rubinstein
Mr. Shmuel (Milky) Rubinstein
Independent Director
Independent Director
--
--
Dr. Shmulik Hess
Dr. Shmulik Hess
Chief Operating Officer, Chief Commercial Officer
Chief Operating Officer, Chief Commercial Officer
--
--
Ms. Hani Luxenburg
Ms. Hani Luxenburg
Chief Financial Officer
Chief Financial Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Ofer Gonen
Mr. Ofer Gonen
Chief Executive Officer, Director
Chief Executive Officer, Director
275.42K
+33.88%
Dr. Vickie R. Driver, M.D.
Dr. Vickie R. Driver, M.D.
Independent Director
Independent Director
--
--
Mr. Stephen T. Wills, CPA
Mr. Stephen T. Wills, CPA
Independent Director
Independent Director
--
--
Dr. Ety Klinger, Ph.D.
Dr. Ety Klinger, Ph.D.
Chief Research and Development Officer
Chief Research and Development Officer
--
--
Mr. Yaron Meyer
Mr. Yaron Meyer
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
--
--
Mr. David Fox
Mr. David Fox
Independent Director
Independent Director
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Mediwound Ltd?
Die fünf größten Anteilseigner von Mediwound Ltd sind: Mr. Ofer Gonen
Wie viele Institutionen halten Anteile an Mediwound Ltd (MDWD)?
Mit Stand vom 2026Q1 halten 165 Institutionen Anteile an Mediwound Ltd, mit einem Gesamtmarktwert von etwa 7.42M, was 57.77% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 298423.00 gestiegen.